Identifying Neoplastic Versus Non-neoplastic Pancreatic Cystic Lesions—What Is the Current Evidence?
Digestive Diseases and Sciences · 2025-10 · 70 (10) · 3246-3259
DOI: 10.1007/s10620-025-09320-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 22.08.2025. Verfasst von Arjun Chatterjee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, …. Hauptthemen laut MEDLINE: Pancreatic Cyst, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The widespread use of modern, high-resolution cross-sectional imaging has led to increased detection of pancreatic cystic lesions (PCLs), which have varying malignant potential. While most require periodic radiographic surveillance, some warrant biopsy or surgical excision.
Methods
We conducted a narrative review of the literature focusing on the diagnostic accuracy of imaging and the role of endoscopic and molecular tools in PCL evaluation.
Results
Cross-sectional imaging correctly classifies cyst type based on morphological features in approximately 50% of cases, with MRI generally outperforming CT. Endoscopic ultrasonography (EUS) is particularly useful when clinical and imaging findings are inconclusive or when high-risk features are present. In selected cases, such features may prompt direct surgical intervention. EUS-guided fine-needle aspiration of cyst fluid for chemical, genetic, and cytological analysis helps differentiate neoplastic mucinous cysts—such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms—from benign, non-mucinous cysts.
Conclusions
Accurate diagnosis of PCLs requires a multimodal approach combining high-quality imaging, EUS evaluation, and cyst fluid analysis. Advances in biomarker development hold promise for improving risk stratification and guiding individualized management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA. chattea2@ccf.org.
- Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Diagnostics Institute, Department of Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Radiology, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of General Surgery, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA.
Zitieren
APA
Chatterjee, A., Prado, R., Fulmer, C. G., Coppa, C., Joyce, D., Mohiuddin, S., Chahal, P., & Stevens, T. (2025). Identifying Neoplastic Versus Non-neoplastic Pancreatic Cystic Lesions—What Is the Current Evidence?. Digestive Diseases and Sciences, 70(10), 3246-3259. https://doi.org/10.1007/s10620-025-09320-4
Vancouver
Chatterjee A, Prado R, Fulmer CG, Coppa C, Joyce D, Mohiuddin S, et al. Identifying Neoplastic Versus Non-neoplastic Pancreatic Cystic Lesions—What Is the Current Evidence?. Digestive Diseases and Sciences. 2025;70(10):3246-3259. doi:10.1007/s10620-025-09320-4
BibTeX
@article{Chatterjee2025,
author = {Chatterjee, Arjun and Prado, Renan and Fulmer, Clifton G and Coppa, Christopher and Joyce, Daniel and Mohiuddin, Syed and Chahal, Prabhleen and Stevens, Tyler},
title = {Identifying Neoplastic Versus Non-neoplastic Pancreatic Cystic Lesions—What Is the Current Evidence?},
journal = {Digestive Diseases and Sciences},
year = {2025},
volume = {70},
number = {10},
pages = {3246--3259},
doi = {10.1007/s10620-025-09320-4}
}
EUVIMED